Secondary prevention in patients with known coronary artery disease;Sekundarprophylaxe bei bekannter chronischer koronarer Herzkrankheit

Schweizerische Medizinische Wochenschrift

Volumn 127, Issue 7, 1997, Pages 254-260

  Hunziker, P ^a   Bertel, O ^a  

^a TRIEMLI HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NIFEDIPINE; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ANGINA PECTORIS; ARTICLE; CORONARY ARTERY DISEASE; DRUG USE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROPHYLAXIS; TRANSLUMINAL CORONARY ANGIOPLASTY; ADULT; AGED; CLINICAL TRIAL; MIDDLE AGED; PROSPECTIVE STUDY; UNSTABLE ANGINA PECTORIS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGINA, UNSTABLE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ANTILIPEMIC AGENTS; ASPIRIN; CALCIUM CHANNEL BLOCKERS; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES;

EID: 0031038851     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Moss AJ, Benhorin J: Prognosis and management after a first myocardial infarction. N Engl J Med 1990; 322: 743-753.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
3. Willard JE, Lange RA, Hillis LD: The use of aspirin in ischemic heart disease. N Engl J Med 1992; 327: 175-181.
4. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH: Low-dose aspirin therapy for chronic stable angina. Ann Intern Med 1991; 114: 835-839.
5. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R: Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989; 80: 749-756.
6. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
7. Smith P, Arnesen H, Holme I: The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-152.
8. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group: Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 499-503.
9. The Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 305: 406-408.
10. Betablocker heart attack trial research group: A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707-1714.
11. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I et al.: Effect on mortality of metoprolol in acute myocardial infarction. A double blind randomized trial. Lancet 1981/II: 823-827.
12. Olsson G, Wikstrand J, Warnold I, Manger Cats V, McBoyle D et al.: Metoprolol-induced reduction in postinfarction mortality: pooled results from five double blind randomized trials. Eur Heart J 1992; 13: 28-32.
13. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ et al., on behalf of the SAVE investigators: Effect of captopril on mortality and morbidity in patients with ventricular dysfunction after myocardial infarction-results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-677.
14. The SOLVD-Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.
15. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E: Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988; 319: 80-86.
16. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
17. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
18. Law MR, Wald NJ, Thompson SG: By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994; 308: 367-372.
19. Furberg CD, Pitt B, Byington RP, Park JS, McGovern ME, for the PLACI and PLACII Investigators: Reduction in coronary events during treatment with pravastatin. Am J Cardiol 1995; 76: 60C-63C.
20. CARE-Studie: Orale Präsentation am Jahreskongress des American College of Cardiology, März 1996.
21. Bush TL, Barret-Connor E, Cowan LD, Criqui MH, Wallace RB et al.: Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1978; 75: 1102-1109.
22. Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63.
23. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B et al.: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325: 756-762.
24. Arbeitsgruppe Lipide der Schweizerischen Gesellschaft für Kardiologie: Wie behandle ich einen Patienten mit mehreren Risikofaktoren für die koronare Herzkrankheit. Empfehlungen der Schweizerischen Gesellschaft für Kardiologie, Angiologie, Gynäkologie und Geburtshilfe, Innere Medizin und Schweizerische Diabetesgesellschaft. Basel, Juni 1995.
25. Stein Y: Comparison of European and USA guidelines for prevention of coronary heart disease. Atherosclerosis 1994; 110 (Suppl.): S41-S44.
26. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J: Blockers and sudden cardiac death. Ann Intern Med 1995; 123: 358-367.
27. Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J Jr: Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990; 11: 43-50.
28. Chadda K, Goldstein S, Ryington R, Curb JD: Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73: 503-510.
29. Arbeitsgruppe Lipide der Schweizerischen Herzstiftung: Lipide und Prävention der koronaren Herzkrankheit: Diagnose und prophylaktische Massnahmen. Schweiz Ärztezeitung 1992; 72: 1-10.
30. American Heart Association/National Heart, Lung, and Blood Institute: The cholesterol facts. A summary of the evidence relation dietary fats, serum cholesterol, and coronary heart disease. Circulation 1990; 81: 1721-1733.
31. Holme I: Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomized trials. Br Heart J 1993; 69 (Suppl.): S42-S47.
32. Hay JW, Wittels EH, Gotto AM: An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease regression. Am J Cardiol 1991; 67: 789-796.
33. Scandinavian Simvastatin Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
34. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
35. Latini R, Maggoni AP, Flather M, Sleight P, Tognoni G: ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 1995; 92: 3132.
36. Furberg CD, Psaty BM, Meyer JV: Nifedipin-dose related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
37. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE et al.: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-625.
38. Burkart F: Secondary and tertiary prevention with calcium antagonists in coronary artery disease. Drugs 1992; 43 (Suppl. 1): 37-42.
39. Antiplatelet Trialist's Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-331.
40. Holme I: Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol 1995; 76: 10C-17C.
41. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G et al.: Effect on mortality of metoprolol in acute myocardial infarction. A double blind randomized trial. Lancet 1981/II: 823-827.
42. Eccles M, Bradshaw C: Use of secondary prophylaxis against myocardial infarction in the north of England. Br Med J 1991; 302: 91-92.
43. Rubowitz AH, Porath A: Secondary prevention of coronary heart disease in patients after acute myocardial infarction at the Soroka Medical Center. Isr J Med Sci 1992; 28: 856-861.
44. ASPIRE Steering Group: A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events) principal results. Heart 1996; 75: 334-342.
45. Angehrn W, Urban P, Stauffer J-Ch, Jolliet PH, Simeon-Dubach et al.: PIMICS: Eine prospektive Erfassung von hospitalisierten Myokardinfarktpatienten in der Schweiz. Schweiz Med Wochenschr 1996; 126 (Suppl. 74/II): 12S.
46. Masciangelo ML, d'Espine M, Urban Ph, Gaspoz JM: Traitements prescrits après un infarctus aigu du myocarde: les publications influencent-elles la pratique? Med Hyg 1995; 53: 1049-1056.
47. Krumholz HM, Radford JM, Ellerbeck EF, Hennen J, Meehan TP et al.: Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med 1996; 124: 292-298.
48. Brandt CM, Wees-Ponchon A, Nisand G, Verdun A, Jobard P et al.: Survie dans l'infarctus du myocarde au stade aigu dans un groupe de 369 patients admis consécutivement entre 1988 et 1992. Arch Mal Cœur Vaiss 1994; 87: 861-868.
49. Clarke KW, Gray D, Keating NA, Hampton JR: Do women with acute myocardial infarction receive the same treatment as men? Br Med J 1994; 309: 563-566.
50. Marques-Vidal P, Cambou JP, Evans A, Arveiler D, Luc G et al.: Medical treatment of myocardial infarction in France and Northern Ireland. Results from the ECTIM study. Enquête cas-témoins de l'infarctus du myocarde. Eur Heart J 1995; 16: 348-353.
51. Schreiber TL, Elkhatib A, Grines CL, O'Neill WW: Cardiologist versus internist management of patients with unstable angina: treatment patterns and outcome. J Am Coll Cardiol 1995; 26: 577-582.
52. Shea S, Gemson DH, Mossel P: Management of high blood cholesterol by primary care physicians: diffusion of the National Cholesterol Education Program Adult Treatment Panel guidelines. J Gen Intern Med 1990; 5: 327-334.
53. Lawson Matthew PJ, Wilson AT, Woodmansey PA, Channer KS: Unsatisfactory management of patients with myocardial infarction admitted to general medical wards. J R Coll Physicians Lond 1994; 28: 49-51.
54. Brooks HR, McGlynn EA, Cleary PD: Measuring quality of care. N Engl J Med 1996; 335: 966-969.